Galectin-3 and Pentraxin-3 as Potential Biomarkers in Chronic Coronary Syndrome and Atrial Fibrillation: Insights from a 131-Patient Cohort

• DOI: 10.20944/preprints202504.2195.v1
• Publication Date: 2025-04-30T01:05:33Z
• Authors: Alexandru- Florin...; Paula Cristina Mo...; Maria Godun; Stefan Dorin Dobr...; Alexandru Jigoranu; Miron Mihnea; Diana Gabriela Iosep; Ana Maria Buburuz; Radu Stefan Miftode; Diana-Elena Floria; Raluca Mitea; Cristina Gena Das...; Daniela Maria Tanase; Irina-Iuliana Cos...; Mariana Floria
• Keywords: Galectin-3

Chronic coronary syndrome (CCS) and atrial fibrillation (AF) are prevalent cardiovascular conditions, between whom there is a dual relationship, with significant morbidity mortality. Recent studies have highlighted the roles of galectin-3 pentraxin-3, as potential biomarkers in atherosclerosis, yet their specific interactions implications patients CCS AF remain underexplored. This study aimed to evaluate levels pentraxin-3 cohort AF. A total 131 diagnosed or/and were stratified based on stenosis severity (significant, S-CCS non-significant, N-CCS lesions) arrhythmia burden. Blood samples collected measure serum using enzyme-linked immunosorbent assay (ELISA) techniques. Clinical data, including demographic information, comorbidities, medication use biological markers systemic inflammation, recorded. The value was more than double compared those (17.39 4.459 ng/mL versus 7.49 2.732 ng/mL, p<0.001). Atrial not associated statistically variations values, neither overall nor separately group or N-CCS. However, similar (2839.18 1521.639 pg/mL 2564.07 1299.055 pg/mL, p=0.417). These values lower sinus rhythm, mean 2469.91 1253.782 steadily increase paroxysmal, persistent permanent AF, for they reach 3162.87 1893.068 pg/mL. underscores Elevated correlate could serve indicator risk stratification, patients’ selection invasive coronarography therapeutic targeting CCS.